Weight-loss jabs could reduce asthma symptoms in obese people, study says
Researchers find a surprising new use for weight-loss jabs
- New research indicates that weight-loss jabs, known as GLP1-RAs, may help reduce asthma symptoms in obese individuals.
- These drugs, originally for type 2 diabetes and now prescribed for obesity, could offer a treatment option for obese asthma patients who are often resistant to traditional steroid therapies.
- A study analysing over 60,000 patient records found that those on GLP1-RAs experienced weight loss and improved asthma control, even with modest weight reductions.
- Experts suggest that GLP1-RAs may affect inflammatory responses in the airways differently from conventional steroids, pointing to a novel therapeutic approach.
- While the findings are promising, further research is required to fully understand the mechanisms by which these drugs improve asthma control and their wider applicability, with calls for increased funding in lung health studies.